BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/19/2026 6:10:56 AM | Browse: 10 | Download: 3
| ISSN |
2219-2824 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Metabolic inflammation in metabolic dysfunction-associated steatotic liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Ye Zhang and Ming Yang |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, Assistant Professor, PhD, Department of Surgery, School of Medicine, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030, United States. minyang@uchc.edu |
| Key Words |
Metainflammation; Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction and alcohol-associated liver disease; Lipid metabolism; Immunity; Liver fibrosis; Clinical trials |
| Core Tip |
Metainflammation contributes to the pathogenesis of numerous metabolic disorders and chronic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-associated liver disease (MetALD). It promotes hepatic lipid accumulation, inflammation, fibrosis, and cell death, thereby accelerating the progression of MASLD or MetALD to cirrhosis and liver cancer. Therapeutic strategies targeting metainflammation, including gut microbiome-directed therapies, dietary modulation, antioxidant interventions, and modulation of lipid metabolism, represent promising therapies for metabolic liver diseases. |
| Publish Date |
2026-11-19 02:35 |
| Citation |
Zhang CY, Yang M. Metabolic inflammation in metabolic dysfunction-associated steatotic liver disease. World J Immunol 2026; 16(3): 125225
|
| URL |
https://www.wjgnet.com/2219-2824/full/v16/i3/125225.htm |
| DOI |
https://doi.org/10.5411/wji.125225 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.